Medical Weight Loss in Des Moines, WA

Dieting relies on caloric restriction and willpower alone, which works short-term for some patients but rarely produces sustained results for those with metabolic or biological barriers to weight loss. Medical weight loss uses FDA-approved medications that address the biological mechanisms of appetite regulation and metabolic function. Combined with physician oversight, lab monitoring, and structured follow-up, the clinical framework makes sustained results significantly more achievable. It is not about willpower. It is about giving your body the clinical support it needs.

The most common side effects of both semaglutide and tirzepatide are gastrointestinal, including nausea, vomiting, diarrhea, and constipation. These are typically mild and most common during dose titration in the first few weeks of treatment. Starting at a low dose and increasing gradually is specifically designed to minimize these effects. Your provider monitors for any concerns throughout the program and adjusts your plan accordingly.

Results vary significantly based on starting weight, metabolic health, the medication prescribed, adherence, and lifestyle factors. Clinical trials of GLP-1 medications have shown average weight loss of 15 to 20 percent of body weight over 12 to 16 months. Some patients exceed these averages, while others may see more modest results. Your provider will discuss realistic expectations based on your individual health profile during the initial consultation.

Program costs depend on the medication prescribed, duration of treatment, and monitoring frequency. We discuss pricing transparently during the initial consultation so there are no surprises. Some patients may have insurance coverage for GLP-1 medications depending on their plan and diagnosis. Our team can help navigate coverage options and discuss available payment plans.

Candidates typically have a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related health condition such as hypertension, type 2 diabetes, or high cholesterol. The initial consultation includes a full health assessment and lab work to determine whether GLP-1 medication is appropriate and safe for you. Medical weight loss is not appropriate for pregnant or breastfeeding individuals, patients with a personal or family history of medullary thyroid carcinoma or MEN2, or patients with active pancreatitis.

Our medical weight loss program is run by licensed providers in a clinical setting with in-person evaluations and comprehensive lab work. Many online services prescribe medication after a brief questionnaire without baseline labs, ongoing monitoring, or in-person follow-up. At Allen Medical Aesthetics, every patient receives a thorough health assessment, lab-driven medication selection, and regular provider check-ins. Dr. Tod Work, MD, serves as medical director, and Brittanie Lane, NP, manages your care throughout the program.

Research shows that some patients regain weight after discontinuing GLP-1 medications if lifestyle changes are not maintained. Our program is designed to help you build sustainable habits during treatment so that when you transition off medication, you have the tools to maintain your results. Your provider will work with you on a gradual tapering plan rather than abrupt discontinuation, and we offer ongoing support after your active treatment phase ends.

Semaglutide (the active ingredient in Ozempic and Wegovy) is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. Tirzepatide (the active ingredient in Mounjaro and Zepbound) targets both GLP-1 and GIP receptors, which may provide enhanced blood sugar control and weight loss for some patients. Clinical trials have shown slightly greater average weight loss with tirzepatide. Your provider will recommend the best option based on your health history, goals, and lab results.